Recurrent Melanoma Completed Phase 1 Trials for Ipilimumab (DB06186)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01703507Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for MelanomaTreatment